Semzuvolimab is under clinical development by United BioPharma and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Semzuvolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UB-421 is under development for the prevention of HIV-1 infections. The drug candidate is administered through intravenous and subcutaneous route. UB-421 is a monoclonal antibody (mAb) dB4C7 immunotherapy for HIV infection (AIDS). The drug candidate is developed based on using UBITh technology.
United BioPharma overview
United BioPharma (UBP) is a biopharmaceutical company that develops and commercializes proprietary vaccine products and immunotherapies for chronic and infectious diseases. It is investigating UB-421, a monoclonal antibody targeting HIV (human immunodeficiency virus), UB-621, a human IgG1 (immunoglobulin G) monoclonal antibody for the treatment of recurrent genital herpes, UB-221 against chronic idiopathic urticaria (CIU), severe asthma, food allergy and atopic dermatitis. The company is also developing UB-923 to treat chronic lymphocytic leukemia (CLL), UB-925, a monoclonal antibody targeting gastric cancer and UB-926 for the treatment of breast cancer. UBP’s proprietary de-fucosylation technology is used to reduce fucosylation and develop antibodies. UBP is headquartered in Hukou, Taiwan.
For a complete picture of Semzuvolimab’s drug-specific PTSR and LoA scores, buy the report here.